Ligand Pharmaceuticals Incorporated Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:LGND
  • CUSIP: 53220K50
  • Web: www.ligand.com
Capitalization:
  • Market Cap: $2.59 billion
  • Outstanding Shares: 20,996,000
Average Prices:
  • 50 Day Moving Avg: $118.34
  • 200 Day Moving Avg: $110.09
  • 52 Week Range: $87.50 - $139.79
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 33.39
  • P/E Growth: 1.30
Sales & Book Value:
  • Annual Revenue: $108.59 million
  • Price / Sales: 23.89
  • Book Value: $18.99 per share
  • Price / Book: 6.51
Profitability:
  • EBIDTA: $51.73 million
  • Net Margins: -2.91%
  • Return on Equity: 2.57%
  • Return on Assets: 1.47%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 0.77%
  • Quick Ratio: 0.74%
Misc:
  • Average Volume: 221,998 shs.
  • Beta: 0.97
  • Short Ratio: 18.54
 
Frequently Asked Questions for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

What is Ligand Pharmaceuticals Incorporated's stock symbol?

Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals Incorporated's earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Tuesday, May, 9th. The company reported $0.39 earnings per share for the quarter, missing analysts' consensus estimates of $0.55 by $0.16. The firm had revenue of $29.27 million for the quarter, compared to analyst estimates of $30.25 million. Ligand Pharmaceuticals Incorporated had a positive return on equity of 2.57% and a negative net margin of 2.91%. Ligand Pharmaceuticals Incorporated's revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 earnings per share. View Ligand Pharmaceuticals Incorporated's Earnings History.

What guidance has Ligand Pharmaceuticals Incorporated issued on next quarter's earnings?

Ligand Pharmaceuticals Incorporated issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $2.70 for the period, compared to the Thomson Reuters consensus estimate of $3.12.

Where is Ligand Pharmaceuticals Incorporated's stock going? Where will Ligand Pharmaceuticals Incorporated's stock price be in 2017?

4 equities research analysts have issued 12-month target prices for Ligand Pharmaceuticals Incorporated's stock. Their forecasts range from $103.00 to $160.00. On average, they expect Ligand Pharmaceuticals Incorporated's stock price to reach $133.60 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.

Who are some of Ligand Pharmaceuticals Incorporated's key competitors?

Who are Ligand Pharmaceuticals Incorporated's key executives?

Ligand Pharmaceuticals Incorporated's management team includes the folowing people:

  • Matthew W. Foehr, President, Chief Operating Officer
  • John L. Higgins, Chief Executive Officer, Director
  • Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
  • Charles S. Berkman J.D., Vice President, General Counsel, Secretary
  • John W. Kozarich, Non-Executive Independent Chairman of the Board
  • Jason M. Aryeh, Independent Director
  • Todd C. Davis, Independent Director
  • John L. LaMattina Ph.D., Independent Director
  • Sunil Patel, Independent Director

Who owns Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock is owned by many different of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (1.84%), Russell Investments Group Ltd. (1.77%), AMI Asset Management Corp (0.66%), Woodstock Corp (0.32%), Fisher Asset Management LLC (0.29%) and Summit Creek Advisors LLC (0.21%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include David M Knott, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.

Who sold Ligand Pharmaceuticals Incorporated stock? Who is selling Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Creative Planning, Independent Portfolio Consultants Inc., Sheets Smith Wealth Management, Parametrica Management Ltd, Fisher Asset Management LLC, BB&T Corp and Court Place Advisors LLC. Company insiders that have sold Ligand Pharmaceuticals Incorporated stock in the last year include Jason Aryeh, John L Higgins, John W Kozarich and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

Who bought Ligand Pharmaceuticals Incorporated stock? Who is buying Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Conestoga Capital Advisors LLC, AMI Asset Management Corp, Aperio Group LLC, State of Alaska Department of Revenue, Woodstock Corp, Congress Asset Management Co. MA and Strs Ohio. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

How do I buy Ligand Pharmaceuticals Incorporated stock?

Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals Incorporated's stock price today?

One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $123.54.


MarketBeat Community Rating for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $133.60 (8.14% upside)

Analysts' Ratings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Deutsche Bank AGReiterated RatingHold$100.00 -> $103.00LowView Rating Details
5/22/2017Roth CapitalSet Price TargetBuy$120.00LowView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
10/5/2016Craig HallumBoost Price Target$150.00 -> $160.00N/AView Rating Details
10/5/2016HC WainwrightReiterated RatingBuy$146.00 -> $160.00N/AView Rating Details
4/13/2016StephensInitiated CoverageOverweight$150.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Earnings by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Earnings History by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.43$0.43$0.43
Q2 20171$0.60$0.60$0.60
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.72View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.20View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.81View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.00View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Latest Headlines for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Source:
DateHeadline
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 24 at 10:17 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - July 23 at 4:21 PM
finance.yahoo.com logoLigand to Report Second Quarter 2017 Results on August 7th
finance.yahoo.com - July 21 at 1:19 AM
streetinsider.com logoLigand Pharma (LGND) Enters Pact with Amgen for Rights to Use Captisol in Formulation of AMG 330
www.streetinsider.com - July 18 at 9:40 PM
finance.yahoo.com logoLigand Signs Agreement with Amgen, Grants Rights to Captisol
finance.yahoo.com - July 18 at 4:38 PM
finance.yahoo.com logoInvest Like "Royalty" With These 3 Stocks
finance.yahoo.com - July 18 at 4:38 PM
streetinsider.com logoLigand Pharma (LGND) Enters Pact with Amgen for Rights to Use Captisol in Formulation of AMG 330 - StreetInsider.com
www.streetinsider.com - July 18 at 6:14 AM
americanbankingnews.com logoDeutsche Bank AG Raises Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Price Target to $103.00
www.americanbankingnews.com - July 17 at 7:15 PM
finance.yahoo.com logoLigand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
finance.yahoo.com - July 17 at 12:55 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Expected to Post Quarterly Sales of $23.54 Million
www.americanbankingnews.com - July 16 at 7:54 AM
americanbankingnews.com logo$0.25 Earnings Per Share Expected for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) This Quarter
www.americanbankingnews.com - July 14 at 6:24 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 27 at 8:44 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Raised to Hold at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - June 23 at 8:20 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) CEO Sells $559,920.00 in Stock
www.americanbankingnews.com - June 23 at 7:15 PM
finance.yahoo.com logoLigand Gets Milestone Payment on Partner Drug FDA Approval
finance.yahoo.com - June 22 at 12:33 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Expected to Post Quarterly Sales of $23.39 Million
www.americanbankingnews.com - June 22 at 10:12 AM
nasdaq.com logoLigand Pharma Earns Milestone Payment On FDA Approval Of Baxdela - Quick Facts
www.nasdaq.com - June 21 at 5:31 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Expected to Post Earnings of $0.23 Per Share
www.americanbankingnews.com - June 20 at 4:06 PM
streetinsider.com logoLigand Pharma (LGND) Partner Melinta Therapeutics Reports FDA ... - StreetInsider.com
www.streetinsider.com - June 20 at 3:49 PM
finance.yahoo.com logoLigand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
finance.yahoo.com - June 20 at 3:49 PM
nasdaq.com logoWhy Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 13 at 8:21 AM
finance.yahoo.com logoWhy Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?
finance.yahoo.com - June 13 at 8:21 AM
americanbankingnews.com logoLigand Pharmaceuticals Inc. (LGND) CEO John L. Higgins Sells 12,000 Shares
www.americanbankingnews.com - June 9 at 10:08 PM
finance.yahoo.com logoFeatured Company News - Viking Therapeutics' VK2809 Shows Encouraging Results in Non-Alcoholic Steatohepatitis
finance.yahoo.com - June 8 at 9:04 AM
streetinsider.com logoLigand Pharma (LGND) to Receive $10M Royalty Fee Following Sale of Certain Product Rights by CorMatrix to Aziyo ... - StreetInsider.com
www.streetinsider.com - June 3 at 12:41 AM
finance.yahoo.com logoLigand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
finance.yahoo.com - June 1 at 7:06 PM
finance.yahoo.com logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : June 1, 2017
finance.yahoo.com - June 1 at 8:54 AM
streetinsider.com logoLigand Pharma (LGND) to Receive $10M Royalty Fee Following Sale of Certain Product Rights by CorMatrix to Aziyo Biologics
www.streetinsider.com - May 31 at 11:42 PM
finance.yahoo.com logoLigand (LGND) Signs Licensing Deal with xCella Biosciences
finance.yahoo.com - May 31 at 6:40 PM
finance.yahoo.com logoLigand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
finance.yahoo.com - May 31 at 6:40 PM
americanbankingnews.com logoLigand Pharmaceuticals Inc. (LGND) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 31 at 7:50 AM
streetinsider.com logoLigand Pharma (LGND) Announces Worldwide OmniAb Platform License Agreement With xCella Biosciences - StreetInsider.com
www.streetinsider.com - May 31 at 5:19 AM
streetinsider.com logoLigand Pharma (LGND) Announces Worldwide OmniAb Platform License Agreement With xCella Biosciences
www.streetinsider.com - May 30 at 10:16 AM
finance.yahoo.com logoLigand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
finance.yahoo.com - May 30 at 10:16 AM
americanbankingnews.com logo$23.92 Million in Sales Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter
www.americanbankingnews.com - May 27 at 8:40 AM
americanbankingnews.com logo$0.23 EPS Expected for Ligand Pharmaceuticals Inc. (LGND) This Quarter
www.americanbankingnews.com - May 25 at 12:22 PM
americanbankingnews.com logoLigand Pharmaceuticals Inc. (LGND) PT Set at $120.00 by Roth Capital
www.americanbankingnews.com - May 23 at 6:58 PM
finance.yahoo.com logoETFs with exposure to Ligand Pharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 5:39 PM
finance.yahoo.com logoLigand to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - May 22 at 10:21 AM
finance.yahoo.com logoLigand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 10:49 AM
americanbankingnews.com logoMatthew W. Foehr Sells 5,621 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock
www.americanbankingnews.com - May 15 at 10:35 PM
americanbankingnews.com logoLigand Pharmaceuticals Inc. (LGND) Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - May 15 at 9:14 AM
americanbankingnews.com logoLigand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sells 37,247 Shares
www.americanbankingnews.com - May 13 at 7:22 AM
nasdaq.com logoLigand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates - Nasdaq
www.nasdaq.com - May 11 at 6:46 PM
nasdaq.com logoLigand Pharmaceuticals Inc Q1 Earnings Fall 7%
www.nasdaq.com - May 10 at 12:52 PM
finance.yahoo.com logoLigand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
finance.yahoo.com - May 10 at 12:52 PM
finance.yahoo.com logoEdited Transcript of LGND earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 12:52 PM
americanbankingnews.com logoLigand Pharmaceuticals Inc. (LGND) Posts Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - May 9 at 10:44 PM

Social

Chart

Ligand Pharmaceuticals Incorporated (LGND) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff